Young people (≤40 years of age) with colorectal cancer (CRC) represent a distinct subgroup with more aggressive disease behaviour compared to older patients. We evaluate whether p53 and bcl-2 could be useful in identifying young patients at higher risk of tumour progression. We reviewed 1340 CRC patients with 58 patients ≤40 years (4.2%). They had more frequent moderately or poorly differentiated mucinous adenocarcinomas (26% versus 12.3%, p = 0.03); higher advanced stage at diagnosis; shorter 5-year overall survival (49.8% versus 71%; p = 0.02); more frequent p53 positive (89.8% versus 72.6%, p < 0.05) and bcl-2 negative (88.0% versus 66.2%, p < 0.05) tumours; no difference in DNA content or proliferation indexes. Moreover, p53+ and bcl-2- resulted in being independent predictors of survival with shorter survival for the p53+/bcl-2- patients. Combining p53 and bcl-2, we could identify young CRC patients at higher risk of progression, who probably require development of a more sophisticated therapeutic approach based on identification of predictive factors. © 2008 Elsevier Ltd. All rights reserved.

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance / Torsello, A.; Garufi, C.; Cosimelli, M.; Diodoro, M. G.; Zeuli, M.; Vanni, B.; Campanella, C.; D'Angelo, C.; Sperduti, I.; Donnorso, R. P.; Cognetti, F.; Terzoli, E.; Mottolese, M.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 44:9(2008), pp. 1217-1222. [10.1016/j.ejca.2008.03.002]

P53 and bcl-2 in colorectal cancer arising in patients under 40 years of age: distribution and prognostic relevance

Torsello A.;Zeuli M.;Vanni B.;Sperduti I.;
2008

Abstract

Young people (≤40 years of age) with colorectal cancer (CRC) represent a distinct subgroup with more aggressive disease behaviour compared to older patients. We evaluate whether p53 and bcl-2 could be useful in identifying young patients at higher risk of tumour progression. We reviewed 1340 CRC patients with 58 patients ≤40 years (4.2%). They had more frequent moderately or poorly differentiated mucinous adenocarcinomas (26% versus 12.3%, p = 0.03); higher advanced stage at diagnosis; shorter 5-year overall survival (49.8% versus 71%; p = 0.02); more frequent p53 positive (89.8% versus 72.6%, p < 0.05) and bcl-2 negative (88.0% versus 66.2%, p < 0.05) tumours; no difference in DNA content or proliferation indexes. Moreover, p53+ and bcl-2- resulted in being independent predictors of survival with shorter survival for the p53+/bcl-2- patients. Combining p53 and bcl-2, we could identify young CRC patients at higher risk of progression, who probably require development of a more sophisticated therapeutic approach based on identification of predictive factors. © 2008 Elsevier Ltd. All rights reserved.
File allegati a questo prodotto
File Dimensione Formato  
Torsello_P53_2008.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 152.36 kB
Formato Adobe PDF
152.36 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11573/1311297
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 24
social impact